The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase (RTK) which directs the expansion of disease cells particularly non-small cell lung cancer (NSCLC). NSCLC development is restrained by EGFR tyrosine kinase inhibitors (TKI, for example, erlotinib or gefitinib. Gefitinib is utilized to treat NSCLC patients who have EGFR changes. EGFR tyrosine phosphorylation is controlled by G protein-coupled receptors (GPCR, for example, the neurotensin (NTS) receptor. EGFR transactivation made by NTS expansion NSCLC cells is restrained by SR48692 (NTSR1 adversary) or gefitinib. SR48692 and gefitinib are synergistic at restraining NSCLC multiplication. The outcomes show that GPCR adversaries can potentiate the impacts of TKI in cancer.